Review Form 1.6

Journal Name:	**Journal of Pharmaceutical Research International**
Manuscript Number:	**Ms_JPRI_87875**
Title of the Manuscript:	**US FDA regulatory framework for generic peptides referring to rDNA origin reference products**
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(https://www.journaljpri.com/index.php/JPRI/editorial-policy)

PART 1: Review Comments

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	**Accept after revision**	
Minor REVISION comments	Grammar should be revise Spelling and typos should be check	
Optional/General comments	Add the following references Rastogi S, Shukla S, Kalaivani M, Singh GN. Peptide-based therapeutics: Quality specifications, regulatory considerations, and prospects. Drug Discovery Today. 2019 Jan 1;24(1):148-62. Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B, Hixon D, Joneckis C, Kozlowski S, Rosenberg A, Schrager L. The FDA's assessment of follow-on protein products: a historical perspective. Nature Reviews Drug Discovery. 2007 Jun;6(6):437-42.	

PART 2:

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	

Reviewer Details:

Name:	**Nidhal Mohammed Salih AL-Janabi**
Department, University & Country	**University of Baghdad, Iraq**